NEW YORK (GenomeWeb) – Personalized cancer therapy firm Perthera, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute announced on Thursday a strategic alliance to integrate omics-related data.
The partners plan to conduct a translational research program to evaluate the utility of integrating next-generation sequencing, proteomic, and phosphoproteomic data in the development of cancer therapeutics and clinical practice. They will work together on clinical protocols that incorporate Perthera's approaches and methodologies to cancer treatment and will assess the impact on disease management and patient outcomes, they said.
Financial and other terms of the agreement were not disclosed.
Based in McLean, Va., Perthera was founded in 2013 and provides molecular diagnostic testing, profiling, and analysis services to create an actionable plan for personalized cancer treatment. The agreement with the Northwestern affiliates follows a partnership it forged in June with the Pancreatic Cancer Action Network to provide molecular diagnostic testing and analysis services to pancreatic cancer patients